We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Earlier this week, FDA Commissioner Scott Gottlieb said that the agency will be diverting funds from pre-market drug reviews to post-market safety surveillance.